Zürich19°Clear
Filtrato per argomento
Ultime notizie e aggiornamenti Novartis dalla Svizzera. Articoli curati dall'IA che coprono argomenti Novartis.
← Mostra tutte le notizieNovartis
Novartis has halted several experimental CAR-T cell-therapy trials after three patients died from immune-related complications. The article should explain what rap-cel is, why the trials were suspended, the known risks of CAR-T treatments and what the decision means for patients and the wider Swiss pharmaceutical sector.
about 4 hours ago · 1 source
Business
Swiss pharmaceutical giant Novartis has announced the acquisition of British start-up Myricx Bio for an initial $1.1 billion, a strategic move to bolster its portfolio of antibody-drug conjugates for treating various solid tumours.
SWI swissinfo.ch
Business
As part of a broader M&A spending spree, Swiss pharmaceutical giant Novartis is set to acquire US biotech firm Avidity Biosciences for approximately $12 billion. The deal is aimed at strengthening Novartis's neuroscience business and is one of the largest transactions in a record-breaking year for Swiss M&A.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis is strengthening its US manufacturing footprint with a new facility in North Carolina. The plant will produce active ingredients for both solid medications and advanced RNA-based therapies as part of a multi-billion dollar investment plan.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis has reported a decline in Q1 turnover, attributing the pressure to the loss of patent protection on billion-euro drugs like Entresto. The company is bracing for a significant impact from copycat drugs throughout the year.
SWI swissinfo.ch
Novartis
Vasant Narasimhan, CEO of Swiss pharma giant Novartis, has been appointed to the board of AI company Anthropic. The move signals a strategic deepening of the ties between the pharmaceutical industry and the world of artificial intelligence, with major implications for future drug development.
SWI swissinfo.ch
Business
Remuneration for top managers in Switzerland continued its upward trend in 2025. A new report reveals that Novartis CEO Vasant Narasimhan and Julius Bär's new head Stefan Bollinger both received compensation packages exceeding CHF20 million.
SWI swissinfo.ch
Business
US policies aimed at lowering prescription drug prices are forcing Swiss pharmaceutical companies like Novartis and Roche to reassess their European strategies. Companies are signing 'Most Favoured Nation' deals to align prices, which could reshape investment and innovation in Switzerland's vital pharma sector.
SWI swissinfo.ch · +1 more
Business
Swiss pharmaceutical giant Novartis has begun construction on a new global biomedical research center in San Diego, USA. The facility is a key part of a planned $23 billion US investment and will focus on neuroscience, oncology, and regenerative medicine, expanding the company's research footprint outside of Switzerland.
SWI swissinfo.ch
Business
Swiss pharmaceutical giant Novartis experienced a stall in revenue growth in the final quarter of 2025, although full-year sales still climbed 8% to CHF 54.5 billion. The company has announced an increased dividend for shareholders but is forecasting slower, single-digit sales growth for the coming year.
SWI swissinfo.ch
business
Swiss pharmaceutical giant Novartis announces closure of recently acquired German biotech firm Morphosys by end of 2025, impacting hundreds of positions.
SWI swissinfo.ch
